N/A
Completed N=375
Contingency Management to Enhance Office-Based Buprenorphine Treatment
Source: ClinicalTrials.gov NCT04024059 ↗Enrolled (actual)
375
Serious AEs
2.9%
Results posted
Mar 2025
Primary outcomePrimary: Buprenorphine Adherence as Assessed by the Percentage of Buprenorphine-positive Urine Samples — 80; 84; 78 percentage of urine samples — p==0.22
Summary
Contingency Management interventions provide incentives to substance abuse patients when patients meet therapeutic goals. This project will compare the effectiveness of two Contingency Management interventions (which the investigators have named "Buprenorphine Adherence and Opiate Abstinence" and "Buprenorphine Adherence Only") and Standard Medical Management for treating adults with opioid use disorder. Participants (N=375) will be randomly assigned to one of the three groups. Buprenorphine Adherence and Opiate Abstinence and Buprenorphine Adherence Only participants will receive incentives for daily buprenorphine use. Buprenorphine Adherence and Opiate Abstinence participants also will receive incentives for providing opiate-negative saliva samples. Daily buprenorphine use and opiate abstinence will both be remotely verified using smartphone-enabled video directly observed therapy (Video DOT). All participants will be receiving or referred to receive buprenorphine treatment and will complete assessments every 4 weeks during a 12-week intervention period.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Buprenorphine Adherence as Assessed by the Percentage of Buprenorphine-positive Urine Samples |
80; 84; 78 | =0.22 |
| PRIMARY Opiate Abstinence as Assessed by the Percentage of Opiate-negative Urine Samples |
83; 85; 80 | =0.202 |
| SECONDARY Buprenorphine Diversion as Assessed by Percentage of Participants Reporting Any Diversion of Buprenorphine |
16.12; 16.28; 18.82 | =0.328 |
Eligibility Criteria
Inclusion Criteria
- Opioid use disorder
- Enrolled in buprenorphine treatment
Exclusion Criteria
- Unwilling or unable to use a smartphone
Data sourced from ClinicalTrials.gov (NCT04024059). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.